Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Cancer statistics, 2010.

Jemal A, Siegel R, Xu J, Ward E.

CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.

2.

Triple-negative breast cancer--current status and future directions.

Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N.

Ann Oncol. 2009 Dec;20(12):1913-27. doi: 10.1093/annonc/mdp492. Epub 2009 Nov 9. Review.

PMID:
19901010
3.

Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.

Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT.

Clin Cancer Res. 2009 Nov 1;15(21):6639-48. doi: 10.1158/1078-0432.CCR-09-0951. Epub 2009 Oct 13.

4.

Feeder-free monolayer cultures of human embryonic stem cells express an epithelial plasma membrane protein profile.

Van Hoof D, Braam SR, Dormeyer W, Ward-van Oostwaard D, Heck AJ, Krijgsveld J, Mummery CL.

Stem Cells. 2008 Nov;26(11):2777-81. doi: 10.1634/stemcells.2008-0365. Epub 2008 Aug 14.

5.

Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.

Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J.

Cancer Res. 2008 Feb 15;68(4):989-97. doi: 10.1158/0008-5472.CAN-07-2017.

6.

Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.

Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NT.

Mol Cancer Ther. 2007 Aug;6(8):2168-77. Epub 2007 Aug 1.

7.

Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.

Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT.

Cancer Res. 2007 Jun 15;67(12):5779-88.

8.

Cancer metastasis: building a framework.

Gupta GP, Massagué J.

Cell. 2006 Nov 17;127(4):679-95. Review.

9.

Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.

Rodríguez-Pinilla SM, Sarrió D, Honrado E, Moreno-Bueno G, Hardisson D, Calero F, Benítez J, Palacios J.

J Clin Pathol. 2007 Sep;60(9):1006-12. Epub 2006 Nov 14.

10.

NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2.

Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H.

Oncogene. 2007 Feb 1;26(5):711-24. Epub 2006 Jul 24.

PMID:
16862183
11.

Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.

Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y.

Cancer Chemother Pharmacol. 2006 May;57(5):693-702. Epub 2005 Dec 16.

PMID:
16362295
12.
13.

Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and tumorigenesis.

Ward KR, Zhang KX, Somasiri AM, Roskelley CD, Schrader JW.

Oncogene. 2004 Feb 12;23(6):1187-96. Erratum in: Oncogene. 2004 Nov 18;23(54):8858. Zhang, Kai-Xiu [corrected to Zhang, Kai-Xin].

PMID:
14961075
14.
15.

Supplemental Content

Support Center